Navigation Links
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET)
Date:7/1/2009

NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  866.272.9941
    International Dial-in Number:  617.213.8895
    Participant Code: 45596036
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 74141589

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                               Media
    Eugenia Shen                            Susan Berg
    BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
    (415) 506-6570                          (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... Source Vitál Apothecary, ... 100 percent pure essential oils, announced the company had a successful visit to the ... annual ECRM event gives companies that work in the nutritional, sports and health industries ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater ... of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than ... her career as an educator interacting with countless women who had little knowledge of ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... Many patients don,t realize that they may ... pharmacy just a few blocks away charges only $25 ... Medicationdiscountcard.com has created a price comparison engine ... their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the hassle ...
(Date:1/19/2017)... According to a study conducted by Persistence Market Research (PMR), ... of 6.5% during the forecast period 2016-2024. According to the study, ... leading market for cryotherapy globally during the forecast period  ... Highlights from the Report  ... supply of gas in order to provide smoother maintenance services to ...
Breaking Medicine Technology: